Outcomes of Recipients of Both Bone Marrow and Solid Organ Transplants: A Review
- 1 September 1998
- journal article
- review article
- Published by Wolters Kluwer Health in Medicine
- Vol. 77 (5), 355-369
- https://doi.org/10.1097/00005792-199809000-00005
Abstract
In this review we examine the clinical outcomes of patients who have received both bone marrow transplantation (BMT) and solid organ transplantation (SOT) and discuss the possible immunologic consequences of the dual transplants. We collected cases through a comprehensive literature search (MEDLINE database, English literature only) covering the years 1990 through 1997 and correspondence with the International Bone Marrow Transplant Registry. Our study selected case reports of patients who have undergone both bone marrow and solid organ transplants; cases in which bone marrow transplantation was undertaken as an adjunct ot induce or augment donor-specific tolerance in a recipient to the transplanted organ were excluded. Clinical characteristics included patient's demographic information, underlying disorders for each transplant, source of donor organ or tissue, time between transplants, and immunosuppressive regimens used to prevent graft-versus-host disease (GVHD) or graft rejection. Clinical outcomes included patient survival, complications of transplantation, and donor-specific tolerance that was experienced in many cases. Twenty-one cases of SOT after BMT and 7 cases of BMT after SOT were reviewed. Solid organ transplantations included lung, liver, cardiac, and kidney for a variety of BMT-related complications including GVHD, hepatic veno-occlusive disease, chronic renal failure, end-stage pulmonary disease, and severe cardiomyopathy. Bone marrow transplants were performed following SOT for aplastic anemia and hematologic malignancies. Clinical outcomes for patients who received both BMT and SOT were variable and depended on transplant indication and degree of histocompatibility. Prior bone marrow transplantation may tolerize for a subsequent organ transplant from the same donor. Conversely, severe GVHD may follow BMT from human leukocyte antigen (HLA)-matched donors following SOT. The favorable survival in this high-risk group of patients may represent a literature review bias (that is, an undetermined number of unsuccessful cases may not have been reported). Nonetheless, dual transplantation is clearly feasible in selected cases.Keywords
This publication has 84 references indexed in Scilit:
- Allogeneic lymphocyte chimerism after clinical lung transplantationTransplant Immunology, 1995
- Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptomsHepatology, 1994
- Graft-versus-host disease in solid organ transplantationTransplant International, 1991
- CYCLOSPORINE BIOAVAILABILITY IN HEART-LUNG TRANSPLANT CANDIDATES WITH CYSTIC FIBROSISTransplantation, 1990
- Use of prostaglandin E1 for prevention of liver veno‐occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantationBritish Journal of Haematology, 1990
- Aplastic Anemia Complicating Orthotopic Liver Transplantation for Non-A, Non-B HepatitisNew England Journal of Medicine, 1988
- Acyclovir for Prevention of Cytomegalovirus Infection and Disease after Allogeneic Marrow TransplantationNew England Journal of Medicine, 1988
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- CHRONIC GRAFT-VERSUS-HOST DISEASE COMPLICATED BY MICRONODULAR CIRRHOSIS AND ESOPHAGEAL VARICESTransplantation, 1986
- CYCLOSPORIN A TO PREVENT GRAFT-VERSUS-HOST DISEASE IN MAN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATIONThe Lancet, 1980